The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Incidence of and Risk Factors for Severe Hepatotoxicity Associated with Antiretroviral Combination Therapy
Open accessAbstract
This retrospective cohort study investigated whether particular antiretroviral agents are associated with a higher risk for developing grade 4 liver enzyme elevations (LEEs) in patients with human immunodeficiency virus (HIV) type 1 infection who are starting to receive highly active antiretroviral therapy (HAART). Grade 4 LEE was defined as aminotransferase levels >10 times the upper limit of normal and >200 U above baseline levels. A multivariate Cox model was used to identify risk factors. The incidence of LEE was 6.3%. No patients died of LEE consequences. Risk factors were higher baseline alanine aminotransferase levels, chronic hepatitis B or C virus infection, antiretroviral therapy-naive patients undergoing their first HAART regimen, recent start of a regimen of nevirapine or high-dose ritonavir, and female sex. In hepatitis B virus (HBV)-coinfected patients, discontinuing lamivudine (3TC) use was a risk factor. In 97% of cases, >or=1 risk factor was present. In HBV-coinfected patients using 3TC, continued use of 3TC should be considered, even if 3TC-resistant HIV strains develop.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Castro, K. G., Ward, J. W., Slutsker, L., Buehler, J. W., Jaffe, H. W., Berkelman, R. L., & Curran, J. W. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/17.4.802 · Cited by 4,349
Lee, W. M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712113372406 · Cited by 2,569
Schaff, Z., & Csmos, G. (1994) · Cited by 1,868
Hammer, S. M., Katzenstein, D. A., Hughes, M. D., Gundacker, H., Schooley, R. T., Haubrich, R. H., Henry, W. K., Lederman, M. M., Phair, J. P., Niu, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610103351501 · Cited by 1,091
Adverse effects of antiretroviral therapy
Carr, A., & Cooper, D. A. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02854-3 · Cited by 1,057
Sulkowski, M. S. (2000) · JAMA · doi:10.1001/jama.283.1.74 · Cited by 950
Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway
Brinkman, K., ter Hofstede, H. J. M., Burger, D. M., Smeitink, J. A. M., & Koopmans, P. P. (1998) · AIDS · doi:10.1097/00002030-199814000-00004 · Cited by 847
Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and Zalcitabine
Collier, A. C., Coombs, R. W., Schoenfeld, D. A., Bassett, R. L., Timpone, J., Baruch, A., Jones, M., Facey, K., Whitacre, C., McAuliffe, V. J., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604183341602 · Cited by 745
Darbyshire, J. (1996) · The Lancet · doi:10.1016/s0140-6736(96)05387-1 · Cited by 509
den Brinker, M., Wit, F. W. N. M., Wertheim-van Dillen, P. M. E., Jurriaans, S., Weel, J., van Leeuwen, R., Pakker, N. G., Reiss, P., Danner, S. A., Jan Weverling, G., et al. (2000) · AIDS · doi:10.1097/00002030-200012220-00011 · Cited by 390
Self-citationHepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy
Martínez, E., Blanco, J. L., Arnaiz, J. A., Pérez-Cuevas, J. B., Mocroft, A., Cruceta, A., Marcos, M. A., Milinkovic, A., García-Viejo, M. A., Mallolas, J., et al. (2001) · AIDS · doi:10.1097/00002030-200107060-00007 · Cited by 349
John, M., Flexman, J., & French, M. A. H. (1998) · AIDS · doi:10.1097/00002030-199817000-00010 · Cited by 251
Lactic Acidosis and Hepatic Steatosis Associated with Use of Stavudine: Report of Four Cases
Miller, K. D., Cameron, M., Wood, L. V., Dalakas, M. C., & Kovacs, J. A. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-3-200008010-00010 · Cited by 211
Hepatotoxicity after introduction of highly active antiretroviral therapy
Rodríguez-Rosado, R., García-Samaniego, J., & Soriano, V (1998) · AIDS · doi:10.1097/00002030-199810000-00025 · Cited by 190
Liver toxicity caused by nevirapine
González de Requena, D., Núñez, M., Jiménez-Nácher, I., & Soriano, V. (2002) · AIDS · doi:10.1097/00002030-200201250-00020 · Cited by 176
Savès, M., Vandentorren, S., Daucourt, V., et al. (1999) · AIDS · doi:10.1097/00002030-199912030-00002 · Cited by 148
Markowitz, M. H., Conant, M. A., Hurley, A., Schluger, R., Duran, M., Peterkin, J. J., Chapman, S., Patick, A. K., Hendricks, A., Yuen, G. J., et al. (1998) · The Journal of Infectious Diseases · doi:10.1086/515312 · Cited by 146
Savès, M., Raffi, F., Clevenbergh, P. A., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.12.3451-3455.2000 · Cited by 115
Severe hepatitis in three AIDS patients treated with indinavir
Bräu, N., Leaf, H. L., Wieczorek, R. L., & Margolis, D. M. (1997) · The Lancet · doi:10.1016/s0140-6736(05)62700-6 · Cited by 111
Lenzo, N. P., Garas, B. A., & French, M. A. (1997) · AIDS · doi:10.1097/00002030-199710001-00003 · Cited by 99
Gisolf, E. H., Dreezen, C., Danner, S. A., et al. (2000) · Clinical Infectious Diseases · doi:10.1086/317449 · Cited by 96
Carr, A. D., Morey, A. L., Mallon, P. W. G., Williams, D., & Thorburn, D. R. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04579-7 · Cited by 83
Hypersensitivity Syndrome Associated with Efavirenz Therapy
Bossi, P., Colin, D., Bricaire, F., & Caumes, É. (2000) · Clinical Infectious Diseases · doi:10.1086/313629 · Cited by 75
Johnson, S., & Baraboutis, J. G. (2000) · JAMA · doi:10.1001/jama.284.21.2722 · Cited by 71
Severe Hepatic Failure Related to Nevirapine Treatment
Cattelan, A. M., Erne, E. M., Salatino, A., Trevenzoli, M., Carretta, G., Meneghetti, F., & Cadrobbi, P. (1999) · Clinical Infectious Diseases · doi:10.1086/520242 · Cited by 70
Brivet, F. G., Nion–Larmurier, I., Mégarbane, B., Slama, A., Brivet, M., Rustin, P., & Münnich, A. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80088-4 · Cited by 54
Sha, B. E., Proia, L. A., & Kessler, H. A. (2000) · JAMA · doi:10.1001/jama.284.21.2717 · Cited by 44
Cited by
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,089
Immune restoration disease after antiretroviral therapy
French, M. A., Price, P., & Stone, S. F. (2004) · AIDS · doi:10.1097/01.aids.0000131375.21070.06 · Cited by 651
Soriano, V., Sulkowski, M., Bergin, C., Hatzakis, A., Cacoub, P., Katlama, C., Cargnel, A., Mauss, S., Dieterich, D., Moreno, S., et al. (2002) · AIDS · doi:10.1097/00002030-200204120-00001 · Cited by 444
SARS-associated viral hepatitis caused by a novel coronavirus: Report of three cases
Chau, T.-N., Lee, K.-C., Yao, H., Tsang, T.-Y., Chow, T.-C., Yeung, Y.-C., Choi, K.-W., Tso, Y.-K., Lau, T., Lai, S.-T., et al. (2004) · Hepatology · doi:10.1002/hep.20111 · Cited by 424
Viral hepatitis and HIV coinfection
Sulkowski, M. S. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.11.009 · Cited by 316
Metadata
- Authors
- Wit, F. W. N. M., Weverling, G. J., Weel, J., Jurriaans, S., & Lange, J. M. A.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-07
- Volume
- 186
- Issue
- 1
- Pages
- 23-31
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2135950944
- Cited by
- 315
- References
- 29
- FWCI
- 21.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.